Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID - imatinib study.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
12 2021
Historique:
revised: 09 08 2021
received: 09 08 2021
accepted: 15 09 2021
pubmed: 6 10 2021
medline: 31 12 2021
entrez: 5 10 2021
Statut: ppublish

Résumé

This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (COVID-19). Total (bound + unbound) and unbound imatinib plasma concentrations obtained from 134 patients with COVID-19 participating in the CounterCovid study and from an historical dataset of 20 patients with gastrointestinal stromal tumor (GIST) and 85 patients with chronic myeloid leukemia (CML) were compared. Total imatinib area under the concentration time curve (AUC), maximum concentration (C

Identifiants

pubmed: 34608769
doi: 10.1002/psp4.12718
pmc: PMC8646516
doi:

Substances chimiques

Acute-Phase Proteins 0
Protein Kinase Inhibitors 0
Imatinib Mesylate 8A1O1M485B

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1497-1511

Subventions

Organisme : Innovative Medicines Initiative 2 Joint Undertaking
ID : 101005142

Informations de copyright

© 2021 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

Psychopharmacology (Berl). 2016 May;233(9):1695-705
pubmed: 26032842
Br J Clin Pharmacol. 2001 Jan;51(1):99-102
pubmed: 11167671
Front Pediatr. 2021 Mar 30;8:607647
pubmed: 33859967
J Crit Care. 2018 Oct;47:99-103
pubmed: 29940406
Clin Pharmacol Ther. 2019 Oct;106(4):831-840
pubmed: 31002385
Annu Rev Pharmacol Toxicol. 1992;32:185-209
pubmed: 1605567
Blood. 2008 Apr 15;111(8):4022-8
pubmed: 18256322
Br J Cancer. 2008 May 20;98(10):1633-40
pubmed: 18475296
Pharmacol Res Perspect. 2015 Mar;3(2):e00131
pubmed: 26038706
J Cell Physiol. 2012 Jun;227(6):2798-803
pubmed: 21938724
Clin Cancer Res. 2013 Feb 15;19(4):949
pubmed: 23386693
Biomed Res Int. 2019 Jun 12;2019:3174896
pubmed: 31309103
Br J Clin Pharmacol. 2018 Sep;84(9):1980-1988
pubmed: 29744898
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32641296
Fundam Clin Pharmacol. 2013 Dec;27(6):690-7
pubmed: 23113675
Leuk Res. 2010 Dec;34(12):1573-5
pubmed: 20688395
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
Eur J Clin Pharmacol. 2010 Apr;66(4):369-74
pubmed: 20111860
Clin Pharmacol Ther. 2021 Apr;109(4):1030-1033
pubmed: 33547636
Nature. 2021 May 7;:
pubmed: 33963326
Lancet Respir Med. 2021 Sep;9(9):957-968
pubmed: 34147142
Clin Cancer Res. 2007 Dec 15;13(24):7394-400
pubmed: 18094422
Mol Pharm. 2021 Mar 1;18(3):754-771
pubmed: 33464914
Med Hypotheses. 2020 Nov;144:110033
pubmed: 32758877
J Clin Pharmacol. 2004 Feb;44(2):158-62
pubmed: 14747424
Neuro Oncol. 2008 Jun;10(3):330-40
pubmed: 18359865
Clin Pharmacokinet. 2020 Oct;59(10):1251-1260
pubmed: 32856282
Eur J Clin Pharmacol. 2009 Jun;65(6):545-9
pubmed: 19214491
Mod Rheumatol. 2013 Sep;23(5):977-85
pubmed: 23099471
Viruses. 2021 Jan 29;13(2):
pubmed: 33572857
Clin Pharmacokinet. 2005;44(9):879-94
pubmed: 16122278
Pharm Res. 2018 Dec 28;36(2):30
pubmed: 30593605
Cancer. 2010 Mar 15;116(6):1419-30
pubmed: 20120030
Am J Physiol Lung Cell Mol Physiol. 2015 Dec 1;309(11):L1294-304
pubmed: 26432864
Leukemia. 2009 Sep;23(9):1537-44
pubmed: 19404318
Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):629-40
pubmed: 16863429
Blood. 2007 Apr 15;109(8):3496-9
pubmed: 17192396
Br J Clin Pharmacol. 2006 Jul;62(1):97-112
pubmed: 16842382
Clin Pharmacol Ther. 2009 Apr;85(4):434-8
pubmed: 19212314
Blood. 2001 Apr 15;97(8):2440-8
pubmed: 11290609
Br J Clin Pharmacol. 2013 Apr;75(4):1007-18
pubmed: 22891806
Drug Metab Dispos. 2011 Aug;39(8):1415-22
pubmed: 21555507
J Clin Oncol. 2009 Jul 1;27(19):3141-7
pubmed: 19451435
Circulation. 2012 Dec 4;126(23):2728-38
pubmed: 23099479
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):1982-96
pubmed: 19505856
CPT Pharmacometrics Syst Pharmacol. 2021 Dec;10(12):1497-1511
pubmed: 34608769
Blood. 2011 Feb 24;117(8):e75-87
pubmed: 20810928
Clin Pharmacokinet. 2012 Mar 1;51(3):187-201
pubmed: 22339450
Clin Cancer Res. 2012 Oct 15;18(20):5780-7
pubmed: 22850565
Clin Pharmacol Ther. 2007 Jul;82(1):17-20
pubmed: 17571070
Clin Pharmacokinet. 2019 Aug;58(8):1069-1075
pubmed: 31111332
J Clin Oncol. 2008 Feb 1;26(4):570-6
pubmed: 18235116
J Clin Oncol. 2004 Mar 1;22(5):935-42
pubmed: 14990650

Auteurs

Imke H Bartelink (IH)

Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Pierre M Bet (PM)

Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Nicolas Widmer (N)

Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Specialised Centre for Emergency and Disaster Pharmacy, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
Pharmacy of the Eastern Vaud Hospitals, Rennaz, Switzerland.

Monia Guidi (M)

Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Erik Duijvelaar (E)

Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Bram Grob (B)

Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Richard Honeywell (R)

Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Amanda Evelo (A)

Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Ivo P E Tielbeek (IPE)

Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Sue D Snape (SD)

Exvastat Ltd., Cambridge, UK.

Henrike Hamer (H)

Department of Clinical Chemistry, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Laurent A Decosterd (LA)

Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Harm Jan Bogaard (H)

Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Jurjan Aman (J)

Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Eleonora L Swart (EL)

Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH